Lead-like compounds for inhibiting Methionine amino peptidase 2 (MetAP2)

Abstract

This research aims to find a new approach to deal with cancer, by targeting a protein that controls the growth and increases the size of the tumour. The approach uses computer-aid drug designed to find the best drug for inhibiting f Methionine Aminopeptidase (Metap2) which is an enzyme that is responsible for starting the synthesis of new protein. The inhibition of the enzyme was found to be crucial in stopping the growth of the tumour and its development. In this research, an in-silico approach was conducted to obtain compounds that are capable of inhibiting the enzyme with non-toxic features. This is done by using Ligand-Based. The Zinc15 and National Institute of Cancer Data (NCI) Databases were screened to attain a variety of manufactured Compounds. Then, molecular docking filtration process was carried out using PyRx, and Autodock4. Finally, SwissADME protocol was used to show the ADMET properties and that compounds can permit the blood barriers and validate better pharmacokinetic properties than the Fumagillin.